NCT03556904 2026-01-15
FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)
University of Michigan Rogel Cancer Center
Phase 2 Completed
Clinical Trials
11 trialsNCT07163910 2025-11-18
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
Zhongda Hospital
Phase 2 Recruiting
NCT06686381 2025-02-05
Tetra-modality Bladder Preservation Strategies in Muscle-invasive Bladder Cancer: TURBT+ Chemo/Immunotherapy+ Radiation Therapy+ Maintenance Immunotherapy vs. W&W
American University of Beirut Medical Center
Phase 2 Not yet recruiting
NCT03248570 2024-11-20
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
University of California, San Francisco
Phase 2 Completed
NCT06427057 2024-05-23
A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors
Tongji Hospital
Phase 2 Not yet recruiting
NCT03700099 2024-04-15
Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT00004026 2020-10-19
CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy
CTI BioPharma
Phase 2 Terminated
NCT01094496 2020-02-13
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Celldex Therapeutics
Phase 2 Terminated
NCT00006376 2013-12-04
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005848 2013-07-11
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Phase 2 Completed
NCT00108290 2008-04-04
Chemotherapy, Hormone Therapy, and Surgery to Remove the Prostate Gland in Patients With High Risk Prostate Cancer
VA Office of Research and Development
Phase 2 Completed